Syndax Pharmaceuticals, Inc. SNDX
9.59 USD +0.10 (+1.05%)
At closeNov 12, 2026, 4:09 AM EST
9.80 +0.21 +2.19%
Pre-market · Nov 12, 4:09 AM ET
9.38 Day range 9.85
9.15 52-week range 25.59
- YTD
- -54.36%
- 1 year
- -45.91%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (“Syndax” or the “Company”) (NASDAQ: SNDX). Such investors are…
globenewswire.com Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for TEM, TWLO, UPWK, MRSH and PLTR; cut MRVL and AAPL targets, with upgrades for TWLO and MRSH.
benzinga.com HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $36.
benzinga.com Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 21.43 percent increase over…
benzinga.com Syndax Pharmaceuticals Suffers Pipeline Blow Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
benzinga.com Crude Oil Edges Higher; Citigroup Earnings Top Views U.S. stocks edged lower; Citi beat Q3 estimates. Bumble and BIO-key surged, while Pershing Square, Cipher Digital and Syndax fell.
benzinga.com Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.- benzinga.com HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.
benzinga.com Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket UnitedHealth rose after Q3 earnings and sales beat estimates; BIO-Key led gainers, while HUB Cyber Security topped premarket losers.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…